Complex therapy of patients with combined hypertension and OA with the addition of a synthetic analogue of melatonin also contributed to a significant decrease in the level of total cholesterol in group I by 13,6% (LDL cholesterol decreased by 29,2%, p < 0,05).
In addition, the inclusion of the drug melatonin in complex therapy led to an increase in the level of ghrelin in fasting blood serum in patients of group I. Its concentration increased by 57% and approached the indicators of the control group.
The obtained results of the study showed a significantly positive effect of melatonin on such indicators of quality of life (QOL), as role functioning (RF), pain intensity (PI), mental health (MH), social functioning (SF) (p < 0,05) in group I compared to group II, which also indicates the expediency of prescribing this drug as one of the components of complex therapy of combined hypertension and OA. Thus, the patients observed an improvement in their mood, a decrease in the feeling of anxiety, adjustment to a positive course of the disease and an understanding of the need for its medical correction.
The scientific novelty of the obtained results is that, for the first time, the application of a complex approach to the early diagnosis of combined hypertension and OA and the need to optimize drug treatment of patients with these diseases has been clinically and pathogenetically substantiated. For the first time, the effectiveness of adding melatotonin to the basic treatment of patients with comorbid hypertension and OA was investigated and its positive effect on their quality of life was determined.
It was clarified that in patients with combined hypertension and OA, compared to patients with hypertension without OA, the BMI and blood pressure indicators are mostly higher than normal, the structural and functional changes of the myocardium are more pronounced, and the manifestations of dyslipidemia are also significant.
Scientific data on low concentrations of melatonin and ghrelin in patients in cases of comorbid course of hypertension and OA with BMI exceeding normal values were supplemented.
The practical significance of the obtained results is that the use of the proposed improved, clinically and pathogenetically justified differentiated algorithm for the diagnosis and treatment of combined hypertension and OA contributes to the improvement of health indicators and quality of life of patients with these pathologies.
The effectiveness of using a synthetic analogue of melatonin at a dose of 3 mg per day for 1 month as a component of the main treatment of patients with combined hypertension and OA has been proven. It has been established that its use has a positive effect on the course of these diseases (there is a rapid approach of blood pressure to target levels, the manifestations of dyslipidemia are reduced, and the severity and intensity of the pain syndrome is also weakened), and on the quality of life of patients.
The use of research results in clinical practice increases the effectiveness of treatment of patients with combined hypertension and OA and improves their quality of life.
